首页> 外文期刊>Frontiers in Pharmacology >Development of an Optimized LC-MS Method for the Detection of Specialized Pro-Resolving Mediators in Biological Samples
【24h】

Development of an Optimized LC-MS Method for the Detection of Specialized Pro-Resolving Mediators in Biological Samples

机译:优化的LC-MS方法开发,用于检测生物样品中的专业前解析介体

获取原文
           

摘要

The cardioprotective and anti-inflammatory effects of long chain omega-3 polyunsaturated fatty acids (n3 PUFA) are believed to be partly mediated by their oxygenated metabolites (oxylipins). In the last two decades interest in a novel group of autacoids termed specialized pro-resolving mediators (SPMs) increased. These are actively involved in the resolution of inflammation. SPMs are multiple hydroxylated fatty acids including resolvins, maresins, and protectins derived from the n3 PUFA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as well as lipoxins derived from arachidonic acid (ARA). In the present paper, we developed an LC-MS/MS method for a comprehensive set of 18 SPMs derived from ARA, EPA, and DHA and integrated it into our targeted metabolomics platform. Quantification was based on external calibration utilizing five deuterated internal standards in combination with a second internal standard for quality assessment of sample preparation in each sample. The tandem mass spectrometric parameters were carefully optimized for sensitive and specific detection. The influence of source parameters of the used AB Sciex 6500 QTRAP instrument as well as electronic parameters and the selection of transitions are discussed. The method was validated/characterized based on the criteria listed in the European Medicines Agency (EMA) guideline on bioanalytical method validation and method performance is demonstrated regarding recovery of internal standards (between 78 ± 4% and 87 ± 3% from 500 μL of human serum) as well as extraction efficacy of SPMs in spiked plasma (intra-day accuracy within ±20 and ±15% at 0.1 and 0.3 nM in plasma, respectively). Based on the lower limit of quantification of 0.02–0.2 nM, corresponding to 0.18–2.7 pg on column, SPMs were generally not detectable/quantifiable in plasma and serum supporting that circulating levels of SPMs are very low, i.e., &0.1 nM in healthy subjects. Following septic shock or peritonitis, SPMs could be quantified in the samples of several patients. However, in these studies with a small number of patients no clear correlation with severity of inflammation could be observed.
机译:据信长链omega-3多不饱和脂肪酸(n3 PUFA)的心脏保护作用和抗炎作用部分是由它们的氧化代谢产物(oxylipins)介导的。在过去的二十年中,人们对新型的自噬类化合物(专门的亲解析介体)的兴趣有所增加。这些积极参与炎症的解决。 SPM是多种羟基化脂肪酸,包括由n3 PUFA二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)衍生而来的间苯二酚,马雷菌素和保护素,以及从花生四烯酸(ARA)衍生出的脂蛋白。在本文中,我们针对来自ARA,EPA和DHA的18种SPM的综合集开发了LC-MS / MS方法,并将其集成到我们的目标代谢组学平台中。定量基于外部校准,其中使用了五个氘代内标和第二个内标,用于评估每个样品中样品的质量。串联质谱参数已针对敏感和特异检测进行了仔细优化。讨论了所用AB Sciex 6500 QTRAP仪器的源参数的影响以及电子参数和过渡的选择。该方法已根据欧洲药品管理局(EMA)关于生物分析方法验证的指南中列出的标准进行了验证/表征,并就内标物的回收率(从500μL人体中提取78±4%至87±3%)证明了方法的性能。血浆中SPM的提取效率(血浆中0.1和0.3 nM时的日内准确度分别在±20%和±15%之内)。根据0.02–0.2 nM的定量下限(相当于色谱柱上的0.18–2.7 pg),血浆和血清中的SPM通常无法检测/定量,这支持SPM的循环水平非常低,即<0.1 nM。健康受试者。在败血性休克或腹膜炎之后,可以在几例患者的样本中对SPM进行定量。然而,在这些针对少数患者的研究中,未观察到与炎症严重程度的明显相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号